OncoMatch/Clinical Trials/NCT06710223
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
Is NCT06710223 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including SD-101 and Cryotherapy for hepatocellular carcinoma.
Treatment: SD-101 · Cryotherapy · Tremelimumab · Durvalumab — The goal of this Phase 1b clinical trial is to evaluate the safety and efficacy of cryoablation and hepatic arterial administration of SD-101 in participants with advanced hepatocellular carcinoma. After this procedure, participants will be treated with tremelimumab and durvalumab every 4 weeks (STRIDE regimen).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
Peripheral absolute neutrophil count ≥ 1000/mm^3; Platelet count ≥ 50,000/ mm^3; Hemoglobin ≥ 8.0 g/dL
Kidney function
creatinine clearance ≥ 50 ml/min
Liver function
Child-Pugh A or Child-Pugh B7 liver function; Total bilirubin ≤ 2.0 x institution's upper limit of normal; ALT or AST ≤ 5 x institution's upper limit of normal; Albumin ≥ 2 g/dL
Cardiac function
Systolic blood pressure <160 mm Hg; no NYHA class III/IV heart failure; no myocardial infarction/active ischemic heart disease within one year; no uncontrolled dysrhythmias; no poorly controlled angina
Child-Pugh A or Child-Pugh B7 liver function. Total bilirubin ≤ 2.0 x institution's upper limit of normal. ALT or AST ≤ 5 x institution's upper limit of normal. Albumin ≥ 2 g/dL. Peripheral absolute neutrophil count ≥ 1000/mm^3. Platelet count ≥ 50,000/ mm^3. Hemoglobin ≥ 8.0 g/dL. Creatinine clearance ≥ 50 ml/min. Systolic blood pressure <160 mm Hg. Cardiac impairment defined as: prior history of cardiovascular disease including heart failure that meets New York Heart Association (NYHA) class III and IV definitions; OR history of myocardial infarction/active ischemic heart disease within one year of study entry; OR uncontrolled dysrhythmias; OR poorly controlled angina.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California, San Diego · San Diego, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify